From Tax Reliefs to Tech Reforms: Our Analysis of R&D Changes in 2023

As the innovation space continuously evolves, Research and Development (R&D) tax reliefs in the UK have been a consistent ally for companies pushing the boundaries of innovation. The year 2023 has held significant shifts in these reliefs, marking a pivotal moment for businesses involved in R&D activities. Understanding these reforms is crucial for businesses as they adjust to new changes. Our analysis seeks to clarify these changes, offering insights that will empower companies to make well-informed decisions in their R&D pursuits.

Overview of R&D Tax Relief Changes

Since their inception, R&D tax reliefs have been instrumental in fuelling the UK’s innovative endeavours. They serve as a financial benefit for businesses investing in research and development, offering substantial benefits to those who qualify. However, 2023 marks a turning point with key reforms introduced. These changes span across the Small and Medium Enterprises (SME) relief and the Research and Development Expenditure Credit (RDEC) scheme, affecting a broad spectrum of businesses engaged in R&D activities.

The amendments reflect the government’s intent to keep the relief schemes robust, competitive, and attuned to contemporary technological advancements. This revision ensures that R&D tax reliefs continue to be a cornerstone in the UK’s innovation landscape.

Detailed Analysis of Changes

Let’s break this down:

  • The UK Government reduced the enhancement rate from 130% to 86% and the surrender rate from 14.5% to 10% for non-R&D-intensive SMEs.
  • An R&D-intensive SME, defined as one investing at least 40% of total outgoings in qualifying R&D, faces these new thresholds.
  • The RDEC rate for larger companies has seen an uptick from 13% to 20%. This increase is especially significant considering the rise in corporation tax rates, affecting companies with varying profit margins differently.

These adjustments in rates are not merely numerical changes but strategic shifts in the UK’s approach to fostering R&D across different business scales.

 

Eligibility Expansion and Compliance Requirements

2023 also ushers in a widened scope for qualifying expenditures. Now, certain costs related to cloud computing solutions, data licensing, and activities in pure mathematics are eligible for relief. This expansion reflects a modernised view of what constitutes R&D in today’s tech-driven world. Businesses leveraging these technologies can now claim a portion of their expenditure, provided it contributes to resolving scientific or technological uncertainties.

However, with expanded eligibility comes tightened compliance. All claims for R&D reliefs must now be:

  • Submitted digitally
  • Accompanied by an additional information form (AIF). This form requires detailed financial and technical descriptions of the R&D projects, categorising costs across specific qualifying areas.

The move towards digital submissions and comprehensive reporting underlines the government’s commitment to curbing abuse of the relief system while ensuring legitimate claims are well-supported and transparent.

 

New Claim Requirements and Compliance

Since the 8th August 2023, submitting an AIF with your R&D claim becomes mandatory. Failure to include this form will result in an automatic rejection of the claim. The AIF demands detailed information about the development work, including a breakdown of costs across nine specified categories and a thorough description of the projects undertaken. The level of detail required in these descriptions is significant. Companies must answer six key questions for each project, ranging from the nature of the scientific or technological advancement sought to the specific uncertainties faced and how they were tackled. This heightened level of scrutiny is a clear indicator of HMRC’s increased focus on ensuring that only genuine, well-documented R&D efforts are rewarded.

As always, we recommend anyone that is unsure about these changes to seek expert advice.

 

Implications for UK Businesses and Future Outlook

These changes, while challenging, offer an opportunity for UK businesses to refine their R&D strategies.

  • For SMEs, the reduced rates may necessitate a more strategic approach to R&D expenditure, focusing on activities that yield the most innovation.
  • Larger corporations must adapt to the increased RDEC rate, aligning their R&D activities with the new eligibility criteria.
  • The postponement of the UK subcontractor requirement until 2024 provides a temporary reprieve for businesses reliant on international talent and resources.

Looking ahead, the proposed merger of SME R&D Tax Relief and RDEC into a single scheme suggests a future of simplified yet stringent R&D tax relief processes. Businesses must stay agile, keeping abreast of these developments to leverage the benefits effectively.

 

Our Perspective on the R&D Tax Relief Changes

From our perspective, the reduction in relief rates for non-R&D-intensive SMEs, while seemingly a drawback, could incentivise more focused and impactful R&D efforts. It encourages businesses to adopt a quality-over-quantity approach to their innovation strategies. Conversely, the increase in the RDEC rate is a welcome change for larger companies, offering them a more substantial incentive to invest in R&D activities.

Despite all of this, the complexity of compliance and the need for detailed reporting present new challenges. Companies must now invest more effort in documenting their R&D activities meticulously. While this may initially seem burdensome, we believe it will lead to a more transparent and accountable R&D landscape in the UK, ultimately benefiting the economy by nurturing true innovation.

 

Advance your Business with SPRK Capital

The changes to R&D tax reliefs in 2023 are a significant update for UK businesses. Understanding and adapting to these changes is essential, but it can be complex. At SPRK Capital, we offer practical support to help your business navigate these reforms. Our team specialises in R&D financial strategies, ensuring your business can make the most of all financial opportunities available.
SPRK Capital are here to help you with straightforward advice and support in managing your R&D tax claims. Get in touch with us on how we can help your business adjust and thrive under the UK innovation framework.

 

More recent posts:

  • Grant Funding

    Secured an Innovate UK Grant? Here’s What You Need to Do After

    As the innovation space continuously evolves, Research and Development (R&D) tax reliefs in the UK have been a consistent ally for companies pushing the boundaries of innovation. The year 2023 has held significant shifts in these reliefs, marking a pivotal
    Read more
  • R&D Tax Credits

    With VC Funding Declining, R&D Advance Funding Can Help with Growth

    As the innovation space continuously evolves, Research and Development (R&D) tax reliefs in the UK have been a consistent ally for companies pushing the boundaries of innovation. The year 2023 has held significant shifts in these reliefs, marking a pivotal
    Read more
  • Information

    How Filing Your Accounts Late Impacts Loan Opportunities

    As the innovation space continuously evolves, Research and Development (R&D) tax reliefs in the UK have been a consistent ally for companies pushing the boundaries of innovation. The year 2023 has held significant shifts in these reliefs, marking a pivotal
    Read more
  • Information

    Net-Zero is Driving UK Innovation

    As the innovation space continuously evolves, Research and Development (R&D) tax reliefs in the UK have been a consistent ally for companies pushing the boundaries of innovation. The year 2023 has held significant shifts in these reliefs, marking a pivotal
    Read more
  • Information

    Why the UK is Investing in Funding Biotech Innovation

    The UK government's recent announcements about innovation funding vividly demonstrate its commitment to making Britain a science and technology superpower by 2030. This commitment is a strategic implementation of substantial innovation finance to propel biotech to new heights.

    Read more